Molecular Imaging in Genetics

Neuroimaging Clinics of North America

Volumn 25, Issue 1, 2015, Pages 17-29

  Leite, José ^a   Hespanhol, Roberta ^a   Buchpiguel, Carlos Alberto ^b  

^a PET CT   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer disease; Genetics; Molecular imaging; Parkinson disease; PET imaging

Indexed keywords

6 FLUORODOPA F 18; ALPHA SYNUCLEIN; APOLIPOPROTEIN E4; BENPERIDOL; CARBON 11; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; PRESENILIN 1; PRESENILIN 2; PROPYLNORAPOMORPHINE; RACLOPRIDE; RADIOPHARMACEUTICAL AGENT; SPIPERONE; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BASAL GANGLION; BRAIN; BRAIN MAPPING; BRAIN METABOLISM; CEREBELLUM; CORPUS STRIATUM; DIAGNOSIS; DIAGNOSTIC USE; DISEASE CLASSIFICATION; DOPAMINERGIC TRANSMISSION; FAMILY HISTORY; GENE; GENE DOSAGE; GENE MUTATION; GENETIC RISK; GENETICS; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; LRRK2 GENE; METABOLIC RATE; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PATHOLOGY; PHENOTYPIC VARIATION; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROCEDURES; RECEPTOR BINDING; SCINTISCANNING; SENSORIMOTOR CORTEX; SNCA GENE; STRIATE CORTEX;

ALZHEIMER DISEASE; BRAIN; DIAGNOSIS; DIAGNOSTIC USE; FLUORODEOXYGLUCOSE F18; GENETICS; HUMANS; MAGNETIC RESONANCE IMAGING; METHODS; MOLECULAR IMAGING; PARKINSON DISEASE; PATHOLOGY; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84964288725     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2014.09.005     Document Type: Review

References (55)

1. Brookmeyer R., Johnson E., Ziegler-Graham K., et al. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
2. Khachaturian Z. The five-five, ten-ten plan for Alzheimer's disease. Neurobiol Aging 1992, 2:197-198.
3. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88(9):1337-1342.
4. Larson E.B., Shadlen M.F., Wang L., et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004, 140(7):501-509.
5. Braskie M.N., Ringman J.M., Thompson P.M. Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis 2011, 2011:490140.
6. Nussbaum R.L. Genome-wide association studies, Alzheimer disease, and understudied populations. JAMA 2013, 309(14):1527-1528.
7. Anchisi D., Borroni B., Franceschi M., et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005, 62(11):1728-1733.
8. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001, 286(17):2120-2127.
9. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001, 32(2):181-184.
10. Kennedy A.M., Frackowiak R.S., Newman S.K., et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995, 186(1):17-20.
11. Perani D., Grassi F., Sorbi S., et al. PET study in subjects from two Italian FAD families with APP717 Val to Ileu mutation. Eur J Neurol 1997, 4:214-220.
12. Sorbi S., de Leon M.J., de Leon M.J., et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. JNucl Med 2006, 47(11):1778-1786.
13. Nikisch G., Hertel A., Kiessling B., et al. Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature. Eur J Med Res 2008, 13(12):579-584.
14. Klunk W.E., Price J.C., Mathis C.A., et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. JNeurosci 2007, 27(23):6174-6184.
15. Remes A.M., Laru L., Tuominen H., et al. Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008, 65(4):540-544.
16. Koivunen J., Pirttilä T., Kemppainen N., et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008, 26(4):378-383.
17. Knight W.D., Okello A.A., Ryan N.S., et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011, 134:293-300.
18. Gatz M., Reynolds C.A., Fratiglioni L., et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63(2):168-174.
19. Laws S.M., Hone E., Gandy S., et al. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. JNeurochem 2003, 84(6):1215-1236.
20. Genin E., Hannequin D., Wallon D., et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011, 16(9):903-907.
21. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. NEngl J Med 1996, 334(12):752-758.
22. Reiman E.M., Chen K., Alexander G.E., et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 2005, 102(23):8299-8302.
23. Reiman E.M., Chen K., Alexander G.E., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 2004, 101(1):284-289.
24. Small G.W., Ercoli L.M., Silverman D.H., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000, 97(11):6037-6042.
25. Reiman E.M., Caselli R.J., Chen K., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(6):3334-3339.
26. Reiman E.M., Chen K., Liu X., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106(16):6820-6825.
27. Green R.C., Cupples L.A., Go R., et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002, 287(3):329-336.
28. Gómez-Tortosa E., Barquero M.S., Barón M., et al. Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol 2007, 64(12):1743-1748.
29. Mosconi L., Brys M., Switalski R., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A 2007, 104(48):19067-19072.
30. Mosconi L., Mistur R., Switalski R., et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72(6):513-520.
31. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
32. Mosconi L., Rinne J.O., Tsui W.H., et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010, 107(13):5949-5954.
33. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259.
34. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
35. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157(11):1015-1022.
36. Bernheimer H., Birkmayer W., Hornykiewicz O., et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. JNeurol Sci 1973, 20(4):415-455.
37. van der Vegt J.P., van Nuenen B.F., Bloem B.R., et al. Imaging the impact of genes on Parkinson's disease. Neuroscience 2009, 164(1):191-204.
38. Firestone J.A., Smith-Weller T., Franklin G., et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005, 62(1):91-95.
39. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 2005, 64(12):2021-2028.
40. Priyadarshi A., Khuder S.A., Schaub E.A., et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001, 86(2):122-127.
41. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7(4):306-318.
42. Nishioka K., Hayashi S., Farrer M.J., et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006, 59(2):298-309.
43. Zimprich A., Biskup S., Leitner P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44(4):601-607.
44. Valente E.M., Abou-Sleiman P.M., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304(5674):1158-1160.
45. Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392(6676):605-608.
46. Bonifati V., Rizzu P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):256-259.
47. Stoessl A.J. Neuroimaging in Parkinson's disease. Neurotherapeutics 2011, 8(1):72-81.
48. Eckert T., Barnes A., Dhawan V. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005, 26(3):912-921.
49. Moerlein S.M., Perlmutter J.S., Markham J., et al. Invivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. JCereb Blood Flow Metab 1997, 17(8):833-845.
50. Seeman P., Guan H.C., Niznik H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989, 3(1):96-97.
51. Laruelle M. Imaging synaptic neurotransmission with invivo binding competition techniques: a critical review. JCereb Blood Flow Metab 2000, 20(3):423-451.
52. Calne D.B., Langston J.W., Martin W.R. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985, 317(6034):246-248.
53. Pellecchia M.T., Varrone A., Annesi G., et al. Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. Mov Disord 2007, 22(4):559-563.
54. Hilker R., Klein C., Ghaemi M., et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001, 49(3):367-376.
55. Adams J.R., van Netten H., Schulzer M., et al. PET inLRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128(Pt 12):2777-2785.